PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS: Poundland Rockets After 99p Stores Acquisition

Fri, 06th Feb 2015 11:35

LONDON (Alliance News) - The following stocks are amongst the biggest risers and fallers within the main London indices midday Friday.
-------
FTSE 100 WINNERS
-------
GlaxoSmithKline, up 1.7%. The company said it has received positive results from a phase III study investigating the combination of dabrafenib and trametinib. Glaxo said the overall survival rates from the combination of the drugs showed a statistically significant fall in the risk of death from combining the pair in comparison to dabrafenib monotherapy in patients with BRAF V600E/K mutation-positive metastatic melanoma.

Capita, up 1.2%. The outsourcing company said it has been approved to join the lead provider framework for NHS England's commissioning support services. Capita said clinical commissioning groups in the UK will be required to re-procure many support services by April 2016 in order to comply with European procurement law. Capita said NHS England anticipates this will result in GBP3 billion to GBP5 billion in services being procured through the framework.
-------
FTSE 100 LOSERS
-------
Barrat Developments, down 2%. Liberum has cut the housebuilder to Hold from Buy, but is raising its price target to 498 pence from 439p.

Compass Group, down 1.9%. Goldman Sachs has cut the catering and outsourcing company to Sell from Neutral, but raised its price target to 1,005p from 980p.
-------
FTSE 250 WINNERS
-------
Poundland, up 10.4%. The discount retailer has snapped up rival 99p Stores for GBP55 million in cash and shares. It will pay GBP47.5 million in cash for its fellow high-street discounter, along with a further GBP7.5 million in shares. Based on its closing price of 357.8 pence on Thursday, that would see Poundland issue 2.1 million shares. The deal will be conditional upon the approval of the UK Competition and Markets Authority, and Poundland has conceded it may have to offer concessions to get the deal passed after initial talks with the regulator.

Premier Farnell, up 3.5%. N+1 has raised the technology company's recommendation to Buy from Sell, whilst cutting its price target to 180 pence from 220p, saying the share price fall following the company's disappointing full-year trading update was "too harsh". The stock fell 6.7% on Thursday.
-------
FTSE 250 LOSERS
-------
Tate & Lyle, down 11.7%. The sugar company said it expects its full year profit to fall below its previous guidance on the back of continuing problems in its bulk ingredients business and said it will take action to try and improve its operation and supply chain following prolonged issues.

Lonmin, down 2.8%. JP Morgan has cut the platinum producer to Neutral from Overweight, and its price target to 190p from 280p.
-------
AIM ALL-SHARE WINNERS
-------
Clean Air Power, up 40%. The company said it has been given a certificate of conformity from the US Environmental Protection Agency for its US Genesis EDGE Dual-Fuel compression-ignited natural gas engine. The certificate means the product meets EPA emissions requirements and is valid in 49 of the country's 50 states. It has also submitted a separate application to the California Air Resources Board.
-------
AIM ALL-SHARE LOSERS
-------
Powerhouse Energy Group, off 14%. The company said it has ceased all of its operations in Switzerland and Germany so it can solely focus on the construction of the company's gasification system in Australia. The company said it will put all of its efforts into constructing the newly designed PHE G-3 UHT gasification system in Australia, and the contract opportunities that stem from it.

Holders Technology, down 9.3%. The group said it swung to a loss in its last financial year on the back of a fall in revenue which outpaced lower costs. Holders, which suppliers laminates and materials for printed circuit boards and provides LED services, recorded a pretax loss of GBP362,000 for the year to November 30, compared with a GBP73,000 profit in the previous year.
--------

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.